Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wei Gao
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Fourth Hospital of Hebei Medical University,
Shandong First Medical University,
Tianjin Medical University
ORCID:
0000-0002-6054-382X
Observed ORCID:
0000-0002-6054-382X
OpenAlex ID:
A5073275449
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
2022
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
·
Cancer Discovery
·
269
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients
2023
·
Yi Pan
, Jia-Tao Zhang
, et al.
·
Cancer Cell
·
125
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer: A Nonrandomized Controlled Trial
2024
·
Song Dong
, Zhen Wang
, et al.
·
JAMA Oncology
·
104
Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study
2023
·
Weihao Zhang
, Kai Zhang
, et al.
·
Frontiers in Immunology
·
57
PDF
Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
2022
·
Surui Liu
, Wei Gao
, et al.
·
Frontiers in Immunology
·
54
Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study
2023
·
Rui Fu
, Jun Huang
, et al.
·
Molecular Oncology
·
27
PDF
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
·
Clinical Cancer Research
·
21
PDF
Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)
2025
·
Wei Gao
, Zhao-Long Pan
, et al.
·
EClinicalMedicine
·
20
PDF
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
2024
·
Song Dong
, Bingfa Yan
, et al.
·
JTO Clinical and Research Reports
·
13
Efficacy and Safety of CT-guided Percutaneous Cryoablation for Hepatocellular Carcinoma at High-risk Sites
2024
·
Weihao Zhang
, Yan Wang
, et al.
·
Academic Radiology
·
11
PDF
Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging
2025
·
Weihao Zhang
, Xiaohui Zhao
, et al.
·
Frontiers in Immunology
·
7
PDF
High expression of autophagy-related gene EIF4EBP1 could promote tamoxifen resistance and predict poor prognosis in breast cancer
2023
·
Shan Yang
, Tian-Li Hui
, et al.
·
World Journal of Clinical Cases
·
6
PDF
Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II trial (DoHAICs study).
2023
·
Wei Zhang
, Wei Gao
, et al.
·
Journal of Clinical Oncology
·
4
PDF
MRDtarget: A heuristic Gaussian approach for optimizing targeted capture regions to enhance Minimal Residual Disease detection
2025
·
Xuwen Wang
, Yanfang Guan
, et al.
·
PLoS Computational Biology
·
1
PDF
Supplementary Table S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Supplementary Table S6 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Supplementary Table S1 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Supplementary Figure S3 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Supplementary Figure S7 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
PDF
Supplementary Figure S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Supplementary Figure S5 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Supplementary Figure S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Supplementary Table S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Supplementary Table S7 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Supplementary Table S5 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
2025
·
Jia-Tao Zhang
, Si-Yang Liu
, et al.
Show more works
View as search
Works count:
43
Citation count:
719
H-index:
10
I10-index:
10
Year
Topic
Type